ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT)

CUSIP: H0036K147

Q1 2024 13F Holders as of 31 Mar 2024

Type / Class
Equity / Common Shares, par value CHF 0.08 per share
Shares outstanding
124,261,423
Total 13F shares
34,683,534
Share change
+715,318
Total reported value
$155,728,721
Put/Call ratio
36%
Price per share
$4.49
Number of holders
36
Value change
+$7,168,355
Number of buys
17
Number of sells
21

Quarterly Holders Quick Answers

What is CUSIP H0036K147?
CUSIP H0036K147 identifies ADCT - ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) as of Q1 2024

As of 31 Mar 2024, ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) was held by 36 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 34,683,534 shares. The largest 10 holders included Redmile Group, LLC, Prosight Management, LP, MORGAN STANLEY, GOLDMAN SACHS GROUP INC, BANK OF AMERICA CORP /DE/, MILLENNIUM MANAGEMENT LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., CITADEL ADVISORS LLC, Vantage Consulting Group Inc, and Blue Owl Capital Holdings LP. This page lists 36 institutional shareholders reporting positions in this security for the Q1 2024 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.